The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent base
The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous β-tricalcium phosphate powder; and iv) a porous β-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.
대표청구항▼
1. A particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising: i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weig
1. A particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising: i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition;ii) a monocalcium phosphate monohydrate powder;iii) a non-porous β-tricalcium phosphate powder; andiv) a porous β-tricalcium phosphate powder. 2. The particulate composition of claim 1, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition. 3. The particulate composition of claim 1, wherein the calcium sulfate hemihydrate powder has a bimodal particle distribution. 4. The particulate composition of claim 3, wherein the calcium sulfate hemihydrate powder has a median particle size of about 5 to about 20 microns. 5. The particulate composition of claim 1, wherein the non-porous β-tricalcium phosphate powder has a median particle size of less than about 20 microns. 6. The particulate composition of claim 1, wherein the porous β-tricalcium phosphate powder exhibits a bimodal particle size distribution. 7. The particulate composition of claim 6, wherein the porous β-tricalcium phosphate powder comprises less than 50% by weight of particles having a particle size up to about 63 microns and greater than 50% by weight of particles having a particle size greater than about 63 microns. 8. The particulate composition of claim 6, wherein the porous β-tricalcium phosphate powder comprises about 25% by weight of particles having a particle size up to about 63 microns and about 75% by weight of particles having a particle size greater than about 63 microns. 9. The particulate composition of claim 1, further comprising non-porous β-tricalcium phosphate granules having a median particle size of at least about 75 microns. 10. The particulate composition of claim 9, wherein the non-porous β-tricalcium phosphate granules have a median particle size of about 75 to about 1,000 microns. 11. The particulate composition of claim 9, wherein the non-porous β-tricalcium phosphate granules are present at a concentration of up to about 20 weight percent based on the total weight of the particulate composition. 12. The particulate composition of claim 9, wherein the non-porous β-tricalcium phosphate granules are present at a concentration of up to about 12 weight percent based on the total weight of the particulate composition. 13. The particulate composition of claim 1, wherein the calcium sulfate hemihydrate is α-calcium sulfate hemihydrate. 14. The particulate composition of claim 1, wherein the calcium sulfate hemihydrate powder has a bimodal particle distribution comprising about 30 to about 60 volume percent of particles having a mode of about 1.0 to about 3.0 microns and about 40 to about 70 volume percent of particles having a mode of about 20 to about 30 microns, based on the total volume of the calcium sulfate hemihydrate powder. 15. The particulate composition of claim 1, wherein the porous β-tricalcium phosphate powder is present at a concentration of between about 5 and about 15 weight percent. 16. The particulate composition of claim 1, wherein the non-porous β-tricalcium phosphate powder has a bimodal particle size distribution comprising about 30 to about 70 volume percent of particles having a mode of about 2.0 to about 6.0 microns and about 30 to about 70 volume percent of particles having a mode of about 40 to about 70 microns based on the total volume of the non-porous β-tricalcium phosphate powder. 17. The particulate composition of claim 1, wherein the non-porous β-tricalcium phosphate powder has a bimodal particle size distribution comprising about 50 to about 65 volume percent of particles having a mode of about 4.0 to about 5.5 microns and about 35 to about 50 volume percent of particles having a mode of about 60 to about 70 microns based on the total volume of the non-porous β-tricalcium phosphate powder. 18. The particulate composition of claim 1, further comprising an accelerant adapted for accelerating the conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate. 19. The particulate composition of claim 18, wherein the accelerant is selected from the group consisting of calcium sulfate dihydrate particles, potassium sulfate particles, and sodium sulfate particles, wherein the accelerant is optionally coated with sucrose. 20. The particulate composition of claim 18, wherein the accelerant is present at a concentration of up to about 1 weight percent based on the total weight of the particulate composition. 21. A particulate composition, comprising: i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition;ii) a monocalcium phosphate monohydrate powder;iii) a non-porous β-tricalcium phosphate powder having a median particle size of less than about 20 microns, the monocalcium phosphate monohydrate powder and the non-porous β-tricalcium phosphate powder being present at a combined concentration of about 3 to about 20 weight percent based on the total weight of the particulate composition;iv) non-porous β-tricalcium phosphate granules having a median particle size of at least about 75 microns and present at a concentration of up to about 20 weight percent based on the total weight of the particulate composition;v) porous β-tricalcium phosphate powder, in an amount of up to about 15 weight percent based on the total weight of the particulate composition; andvi) an accelerant adapted for accelerating the conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate, the accelerant being present at a concentration of up to about 1 weight percent based on the total weight of the particulate composition. 22. A particulate composition, comprising: i) an α-calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition, and wherein the calcium sulfate hemihydrate powder has a bimodal particle distribution comprising about 30 to about 60 volume percent of particles having a mode of about 1.0 to about 3.0 microns and about 40 to about 70 volume percent of particles having a mode of about 20 to about 30 microns, based on the total volume of the calcium sulfate hemihydrate powder;ii) a monocalcium phosphate monohydrate powder;iii) a β-tricalcium phosphate powder having a median particle size of less than about 20 microns, the monocalcium phosphate monohydrate powder and the β-tricalcium phosphate powder being present at a combined concentration of about 3 to about 20 weight percent based on the total weight of the particulate composition;iv) β-tricalcium phosphate granules having a median particle size of about 100 to about 400 microns and present at a concentration of up to about 12 weight percent based on the total weight of the particulate composition;v) porous β-tricalcium phosphate powder, in an amount of up to about 15 weight percent based on the total weight of the particulate composition, wherein the porous β-tricalcium phosphate powder comprises less than 50% by weight of particles having a particle size up to about 63 microns and greater than 50% by weight of particles having a particle size greater than about 63 microns; andvi) an accelerant adapted for accelerating the conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate, the accelerant being present at a concentration of up to about 1 weight percent based on the total weight of the particulate composition. 23. The particulate composition of claim 1, further comprising a biologically active agent. 24. The particulate composition of claim 23, wherein the biologically active agent is selected from the group consisting of cancellous bone chips, growth factors, antibiotics, pesticides, chemotherapeutic agents, antivirals, analgesics, and anti-inflammatory agents. 25. The particulate composition of claim 23, wherein the biologically active agent is bone marrow aspirate. 26. The particulate composition of claim 23, wherein the biologically active agent is a growth factor selected from the group consisting of fibroblast growth factors, platelet-derived growth factors, bone morphogenic proteins, osteogenic proteins, transforming growth factors, LIM mineralization proteins, osteoid-inducing factors, angiogenins, endothelins; growth differentiation factors, ADMP-1, endothelins, hepatocyte growth factor and keratinocyte growth factor, heparin-binding growth factors, hedgehog proteins, interleukins, colony-stimulating factors, epithelial growth factors, insulin-like growth factors, cytokines, osteopontin, and osteonectin. 27. The particulate composition of claim 1, wherein the particulate composition has a Vicat set time upon mixing with an aqueous solution of about 3 to about 8 minutes. 28. The particulate composition of claim 1, wherein the particulate composition has a Gillmore set time upon mixing with an aqueous solution of about 6 to about 20 minutes. 29. The particulate composition of claim 1, wherein the pore sizes of the porous β-tricalcium phosphate powder are in the range of about 100 microns to about 400 microns. 30. The particulate composition of claim 1, wherein the porous β-tricalcium phosphate powder is characterized by an interconnected, multidirectional porosity. 31. The particulate composition of claim 1, wherein the porous β-tricalcium phosphate powder has a total porosity of at least about 50%. 32. A bone graft substitute cement comprising the reaction product formed by mixing a particulate composition of claim 1 with an aqueous solution, the reaction product comprising calcium sulfate dihydrate, brushite, and a porous β-tricalcium phosphate component. 33. The bone graft substitute cement of claim 32, further comprising non-porous β-tricalcium phosphate granules. 34. The bone graft substitute cement of claim 32, wherein said cement is cast in a predetermined shape. 35. The bone graft substitute cement of claim 34, wherein said predetermined shape is selected from the group consisting of pellets, granules, wedges, blocks, and disks. 36. The bone graft substitute cement of claim 32, wherein the aqueous solution further comprises a carboxylic acid. 37. The bone graft substitute cement of claim 36, wherein the carboxylic acid is a hydroxy carboxylic acid. 38. The bone graft substitute cement of claim 37, wherein the hydroxy carboxylic acid is glycolic acid. 39. The bone graft substitute cement of claim 36, wherein the carboxylic acid is neutralized to a pH of about 6.5 to about 7.5. 40. The bone graft substitute cement of claim 36, wherein the aqueous solution further comprises sodium chloride. 41. A method for treating a bone defect, comprising applying a bone graft substitute cement according to claim 32 to the site of the bone defect. 42. A bone graft substitute kit, comprising one or more containers enclosing a particulate composition according to claim 1, a separate container enclosing a sterile aqueous solution, and a written instruction set describing a method of using the kit. 43. The bone graft substitute kit of claim 42, further comprising a mixing apparatus adapted for mixing the particulate composition and the aqueous solution. 44. The bone graft substitute kit of claim 43, further comprising a delivery device adapted for delivering a bone graft substitute cement mixture to the site of a bone defect. 45. The bone graft substitute kit of claim 44, wherein the delivery device comprises a needle. 46. The bone graft substitute kit of claim 42, wherein a portion of the particulate composition is enclosed in a first syringe and a portion of the particulate composition is enclosed in a second syringe, and wherein the kit further includes a syringe connector adapted to connect the first and second syringe such that the contents of each syringe can be mixed. 47. The bone graft substitute kit of claim 42, further comprising at least one syringe containing at least a portion of the particulate composition and a vial adaptor adapted to connect the syringe to the container enclosing the sterile aqueous solution.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (122)
Stevenson Sharon ; Gertzman Arthur A., Allograft tissue material for filling spinal fusion cages or related surgical spaces.
Genge, Brian R.; Wu, Licia; Sauer, Glenn R.; Wuthier, Roy E.; Genge, Ronald, Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement.
Norton Richard L. (Fort Collins CO) Knight Stephen Michael Gregory (Fort Collins CO) Tipton Arthur J. (Birmingham AL), Biodegradable polymeric composition.
Riess Guido (Garmisch-Partenkirchen DEX) Geiger Albert (Garmisch-Partenkirchen DEX), Bone implant member for prostheses and bone connecting elements and process for the production thereof.
Chae, Soo Kyung; Kim, Hong Yeoul; Lee, Ho Yeon; Lee, Chang Hun; Seo, Kang Moon, Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material.
Liu Sung-Tsuen (29 Landing Laguna Niguel CA 92677) Chung Harvey H. (43 Via Costa Verde Rancho Palos Verdes CA 90274), Calcium phosphate calcium sulfate composite implant material.
Takagi Shigehide (Tokyo JPX) Ito Kuniomi (Tochigi-ken JPX) Hidaka Tsuneo (Tokyo JPX), Ceramic device providing an environment for the promotion and formation of new bone.
Brown Walter E. (Rockville MD) Chow Laurence C. (Germantown MD), Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements.
Moseley, Jon P.; Carroll, Michael E.; McCanless, Jonathan D.; Schulz, Olaf; Fronk, Andy, Composite bone graft substitute cement and articles produced therefrom.
Moseley, Jon P.; Carroll, Michael E.; McCanless, Jonathan D.; Schulz, Olaf; Fronk, Andy, Composite bone graft substitute cement and articles produced therefrom.
Randolph Donald A. (Wheaton IL) Negri Jodi L. (Lakevilla IL) Devine Timothy R. (Whitefish Bay WI) Gitelis Steven (Oakbrook IL), Controlled dissolution pellet containing calcium sulfate.
Yim Kalvin W. K. (N. andover MA) Huberty Michael C. (Andover MA) Northey ; Jr. Richard P. (Ipswich MA) Schrier Jay A. (Andover MA), Formulations for delivery of osteogenic proteins.
Ricci John ; Alexander Harold ; Berman Charles L. ; Frenkel Sally ; Hollander Bruce ; Pecora Gabriele,ITX, Implantation of surgical implants with calcium sulfate.
Cole,Jantzen A.; Carroll,Michael E.; Moseley,Jon P.; Richelsoph,Kelly C., Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects.
Constantz Brent R. (Scott Valley CA) Barr Bryan (Mountain View CA) McVicker Kevin (Fremont CA), Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite.
Barlow Joel W. (7139 Valburn Dr. Austin TX 78731) Lee Goonhee (3357 Lake Austin Blvd. #C Austin TX 78703) Crawford Richard H. (912 Lipan Trail Austin TX 78733) Beaman Joseph J. (700 Texas Ave. Austin, Method for fabricating artificial bone implant green parts.
Ducheyne Paul (Bryn Mawr PA) Cuckler John (Haverford PA) Radin Shulamit (Cherry Hill NJ), Method of depositing calcium phosphate cermamics for bone tissue calcification enhancement.
Lee Dosuk D. ; Rey Christian,FRX ; Aiolova Maria ; Tofighi Aliassghar, Methods and products related to the physical conversion of reactive amorphous calcium phosphate.
Hanker Jacob S. (Chapel Hill NC) Terry Bill C. (Chapel Hill NC) Ambrose Wallace W. (Chapel Hill NC) Lupton Cecel R. (Chapel Hill NC), Plaster of Paris as a bioresorbable scaffold in implants for bone repair.
Broemer Heinz (Hermannstein DEX) Adam Werner (Hermannstein DEX) Hedrich Friedhelm (Edingen DEX), Prosthesis parts provided with a coating of a bio-active material.
Liu Sung-Tsuen (29 Landing Laguna Niguel CA 92677) Chung Harvey H. (43 Via Costa Verde Rancho Palos Verdes CA 90274), Resorbable bioactive calcium phosphate cement.
Liu Sung-Tsuen (29 Landing Laguna Niguel CA 92677) Chung Harvey H. (43 Via Costa Verde Rancho Palos Verdes CA 90274), Resorbable bioactive phosphate containing cements.
Farris Edward T. (4715 Greenville Ave. Dallas TX 75206) Barsa John J. (60 Haven Ave. New York NY 10032) Lagow Richard J. (6204 Shadow Mountain Dr. Austin TX 78731) Capano Paul J. (1730 E. Oltorf Aust, Solid calcium phosphate materials.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.